Evaluating the feasibility of a pharmacist-guided patient-driven intervention to improve blood pressure control in patients with CKD.

Adherence Blood pressure Implementation science

Journal

Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536

Informations de publication

Date de publication:
2019
Historique:
received: 24 10 2018
accepted: 31 01 2019
entrez: 27 2 2019
pubmed: 26 2 2019
medline: 26 2 2019
Statut: epublish

Résumé

Self-titration of blood pressure (BP) medications and lifestyle modifications are effective and safe strategies to lower BP. We assessed the feasibility of implementing a pharmacist-guided, patient-driven self-titration protocol and standardized dietary counseling to improve BP in the chronic kidney disease (CKD) clinic. Adult patients seen in the CKD clinic were identified via registry screening. Inclusion criteria were as follows: a diagnosis of hypertension, average of the last 3 office BP > 150/90 mmHg, and prescribed 3 or fewer BP medications. Patients with severe hypertension were excluded. BP goals were established and patients were referred to the clinical pharmacist who provided them a BP cuff, a BP medication titration plan (based on home BP monitoring), and dietary education. The following outcomes were evaluated: appeal of the program to patients identified by the registry, patient adherence to the protocol and 6-month office BP, and provider attitudes and acceptance of the protocol. Seventeen patients enrolled in the pilot, the majority recruited via clinic schedule screening. Eleven of the 17 patients completed a 6-month office follow-up visit. Three of the 11 patients met their pre-specified office BP goal. There was, however, significant improvement in 6-month office systolic and diastolic BP. Twelve of 17 patients were adherent to entering home BP in EMR. Provider satisfaction with the protocol was high. Our preliminary data suggest that patient-driven self-titration of BP medications is feasible and well received by providers. Future studies are needed to validate these findings and to evaluate the safety and efficacy of this approach.

Sections du résumé

BACKGROUND BACKGROUND
Self-titration of blood pressure (BP) medications and lifestyle modifications are effective and safe strategies to lower BP. We assessed the feasibility of implementing a pharmacist-guided, patient-driven self-titration protocol and standardized dietary counseling to improve BP in the chronic kidney disease (CKD) clinic.
METHODS METHODS
Adult patients seen in the CKD clinic were identified via registry screening. Inclusion criteria were as follows: a diagnosis of hypertension, average of the last 3 office BP > 150/90 mmHg, and prescribed 3 or fewer BP medications. Patients with severe hypertension were excluded. BP goals were established and patients were referred to the clinical pharmacist who provided them a BP cuff, a BP medication titration plan (based on home BP monitoring), and dietary education. The following outcomes were evaluated: appeal of the program to patients identified by the registry, patient adherence to the protocol and 6-month office BP, and provider attitudes and acceptance of the protocol.
RESULTS RESULTS
Seventeen patients enrolled in the pilot, the majority recruited via clinic schedule screening. Eleven of the 17 patients completed a 6-month office follow-up visit. Three of the 11 patients met their pre-specified office BP goal. There was, however, significant improvement in 6-month office systolic and diastolic BP. Twelve of 17 patients were adherent to entering home BP in EMR. Provider satisfaction with the protocol was high.
CONCLUSION CONCLUSIONS
Our preliminary data suggest that patient-driven self-titration of BP medications is feasible and well received by providers. Future studies are needed to validate these findings and to evaluate the safety and efficacy of this approach.

Identifiants

pubmed: 30805198
doi: 10.1186/s40814-019-0410-0
pii: 410
pmc: PMC6373009
doi:

Types de publication

Journal Article

Langues

eng

Pagination

23

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL139918
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007135
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002537
Pays : United States

Déclaration de conflit d'intérêts

The project was submitted for approval to the Colorado Institutional Review Board (COMIRB) with a declaration of the intent to publish. COMIRB viewed the pilot as a quality improvement initiative, and the review was waived. As such, informed consent was not required or obtained.Not applicable as the manuscript does not contain any individual data.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Références

J Gen Intern Med. 2004 Sep;19(9):917-24
pubmed: 15333055
J Clin Hypertens (Greenwich). 2006 Mar;8(3):174-80
pubmed: 16522994
J Clin Hypertens (Greenwich). 2007 Feb;9(2):113-9
pubmed: 17268216
Patient Educ Couns. 2008 Jul;72(1):115-21
pubmed: 18328663
N Engl J Med. 2008 May 1;358(18):1887-98
pubmed: 18378519
J Clin Hypertens (Greenwich). 2008 Apr;10(4):260-71
pubmed: 18401223
Nephrol Dial Transplant. 2008 Dec;23(12):3851-8
pubmed: 18641082
J Clin Hypertens (Greenwich). 2008 Nov;10(11):850-5
pubmed: 19128274
Arch Intern Med. 2010 Jan 25;170(2):126-35
pubmed: 20101007
BMC Fam Pract. 2010 Feb 01;11:8
pubmed: 20113530
Hypertension. 2010 May;55(5):1199-205
pubmed: 20212264
N Engl J Med. 2010 Apr 29;362(17):1575-85
pubmed: 20228401
Ann Med. 2010 Jul;42(5):371-86
pubmed: 20504241
Lancet. 2010 Jul 17;376(9736):163-72
pubmed: 20619448
Arch Intern Med. 2010 Oct 11;170(18):1634-9
pubmed: 20937921
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
JAMA. 2013 Jul 3;310(1):46-56
pubmed: 23821088
JAMA. 2014 Feb 5;311(5):507-20
pubmed: 24352797
JAMA. 2014 Apr 9;311(14):1424-9
pubmed: 24682242
JAMA. 2014 Aug 27;312(8):799-808
pubmed: 25157723
J Gen Intern Med. 2015 May;30(5):556-64
pubmed: 25373831
Pharmacotherapy. 2015 Apr;35(4):e39-50
pubmed: 25884536
Lancet. 2015 Oct 17;386(10003):1588-98
pubmed: 26530623
N Engl J Med. 2015 Nov 26;373(22):2103-16
pubmed: 26551272
Ann Fam Med. 2016 Jan-Feb;14(1):63-9
pubmed: 26755785
J Am Coll Cardiol. 2018 May 15;71(19):e127-e248
pubmed: 29146535
Curr Hypertens Rep. 2018 Jan 18;20(1):1
pubmed: 29349522
BMC Med Educ. 2018 Jun 27;18(1):153
pubmed: 29945578
Arch Intern Med. 1997 Jul 14;157(13):1413-8
pubmed: 9224218

Auteurs

Charles Hopley (C)

1Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Center, Aurora, CO USA.

Emily Andrews (E)

1Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Center, Aurora, CO USA.

Patrick Klem (P)

2Kidney and Hypertension Clinic, University of Colorado Hospitals, Aurora, CO USA.

Michelle Jonjak (M)

2Kidney and Hypertension Clinic, University of Colorado Hospitals, Aurora, CO USA.

Ann Grothe (A)

2Kidney and Hypertension Clinic, University of Colorado Hospitals, Aurora, CO USA.

Patrick Ten Eyck (P)

3Institute for Clinical and Translational Science, University of Iowa, Iowa City, IA USA.

Zhiying You (Z)

1Division of Renal Diseases and Hypertension, University of Colorado Anschutz Medical Center, Aurora, CO USA.

Sarah J Billups (SJ)

4University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Anschutz Medical Center, Aurora, CO USA.

Corey Lyon (C)

5AF Williams Family Medicine Center at Stapleton, University of Colorado Anschutz Medical Center, Aurora, CO USA.

Korey Kennelty (K)

6Department of Pharmacy Practice and Science, College of Pharmacy, University of Iowa, Iowa City, IA USA.
7Department of Family Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA USA.

Bradley Dixon (B)

8Nephrology Division, Carver College of Medicine, University of Iowa, 200 Hawkins Dr., E300C-GH, Iowa City, IA 52242 USA.

Diana Jalal (D)

8Nephrology Division, Carver College of Medicine, University of Iowa, 200 Hawkins Dr., E300C-GH, Iowa City, IA 52242 USA.

Classifications MeSH